Malignant carcinoid syndrome: Survival in the octreotide LAR era

Anthony, Lowell; Kang, Taejin; Shyr, Yi‐Ming

doi:10.1200/jco.2005.23.16_suppl.4084

“…Baseline characteristics were similar between the two groups. Survival in the octreotide LAR group was significantly higher: 229 months compared with 143 months in the control group ( p <0.0001) 13 . Thus, patients with carcinoid syndrome who received treatment with octreotide LAR had a 66% lower risk of death than patients receiving therapy with subcutaneous octreotide in this study 13 .…”

Section: Clinical Experience With Octreotidementioning

confidence: 85%

“…In a retrospective analysis, survival was compared in 145 patients with carcinoid syndrome who were receiving octreotide LAR to 90 patients who had received subcutaneous octreotide 13 . Baseline characteristics were similar between the two groups.…”

Section: Clinical Experience With Octreotidementioning

confidence: 99%

See 1 more Smart Citation

From somatostatin to octreotide LAR: evolution of a somatostatin analogue

Anthony

¹

,

Freda

²

2009

Current Medical Research and Opinion

View full text Add to dashboard Cite

Background Acromegaly is characterized by overproduction of growth hormone (GH) by the pituitary gland. GH stimulates the synthesis of insulin-like growth factor-I (IGF-I), and the somatic growth and metabolic dysfunction that characterize acromegaly are a consequence of elevated GH and IGF-I levels. Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare, slow-growing neoplasms that have usually metastasized by the time of diagnosis. The majority of GEP-NETs are carcinoid tumors whose syndrome is caused by the hypersecretion of biogenic amines, peptides and polypeptides responsible for the principal symptoms of diarrhea and flushing. Methods The MEDLINE and EMBASE databases were searched for preclinical and clinical studies of octreotide (Sandostatin*), a potent synthetic somatostatin analogue, in patients with acromegaly or GEP-NETs. Objective This article reviews the 20 years of clinical experience with octreotide and the impact it has made in patients with acromegaly or GEP-NETs. Results Octreotide has proven to be an essential component in the management strategy of acromegaly and GEP-NETs over the past 20 years. The multiple beneficial effects of octreotide throughout the body, combined with its established safety profile (the most common adverse effects are injection-site pain and gastrointestinal events), have made it an appealing option for clinicians. The advent of the long-acting release (LAR) formulation of octreotide provided additional benefits to patients through monthly administration, while maintaining the efficacy and tolerability profile of the daily subcutaneous formulation. Conclusions Octreotide is a potent synthetic somatostatin analogue that has become the mainstay of medical therapy for tumor control in neuroendocrine disorders such as acromegaly and GEP-NETs. The development of octreotide LAR offered a further advancement; less frequent dosing provided valuable benefits in quality of life to patients, with equivalent efficacy and tolerability. Moreover, recent results from the PROMID study have confirmed the antiproliferative effect of octreotide LAR in patients with well-differentiated metastatic GEP-NETs of the midgut. New therapeutic uses of octreotide are currently under investigation in a variety of clinical settings.

show abstract

“…24 A retrospective study compared survival in 145 patients with carcinoid syndrome who received octreotide LAR between 1996 and 2004 to 90 patients who received SC octreotide between 1986and 1995. Patients who received treatment with octreotide LAR had a 66 % (range 46-82 %) lower risk of death than patients who had received SC octreotide (p<0.0001) 25.…”

mentioning

confidence: 91%

Octreotide – A Review of its Use in Treating Neuroendocrine Tumours

Costa

¹

,

Gumz

²

2010

European Endocrinology

View full text Add to dashboard Cite

Neuroendocrine tumours (NETs) are a heterogeneous group of neoplasms whose incidence has dramatically increased in recent years. Octreotide is a somatostatin analogue used in the treatment of NETs, and its use in clinical trials has been associated with substantially increased survival. Although traditionally used for the relief of symptoms that result from release of peptides and neuroamines, there has been a growing body of evidence that suggest octreotide has antiproliferative effects. A phase III clinical study has demonstrated that the long-acting formulation (LAR), octreotide LAR, lengthens time to tumour progression in patients with well-differentiated metastatic midgut NETs, and that octreotide LAR is a treatment option for patients with metastatic midgut NETs, regardless of functional status. Furthermore, octreotide LAR has demonstrated clinical efficacy in different types of NETs. These data, along with emerging data on somatostatin analogs, may change the way doctors approach this patient population and reinforce the use of these drugs as a treatment option for patients with non-functioning tumours.

show abstract

“…A retrospective study compared survival in 145 patients with carcinoid syndrome who received octreotide LAR between 1996 and 2004 to 90 patients who received SC octreotide between 1986 and 1995. Patients who received treatment with octreotide LAR had a 66 % (range 46-82 %) lower risk of death than patients who had received SC octreotide (p<0.0001) 25.…”

mentioning

confidence: 91%

Octreotide – A Review of its Use in Treating Neuroendocrine Tumours

Costa¹,

Gumz²

2013

European Oncology &Amp; Haematology

View full text Add to dashboard Cite

Neuroendocrine tumours (NETs) are a heterogeneous group of neoplasms whose incidence has dramatically increased in recent years. Octreotide is a somatostatin analogue used in the treatment of NETs, and its use in clinical trials has been associated with substantially increased survival. Although traditionally used for the relief of symptoms that result from release of peptides and neuroamines, there has been a growing body of evidence that suggest octreotide has antiproliferative effects. A phase III clinical study has demonstrated that the long-acting formulation (LAR), octreotide LAR, lengthens time to tumour progression in patients with well-differentiated metastatic midgut NETs, and that octreotide LAR is a treatment option for patients with metastatic midgut NETs, regardless of functional status. Furthermore, octreotide LAR has demonstrated clinical efficacy in different types of NETs. These data, along with emerging data on somatostatin analogs, may change the way doctors approach this patient population and reinforce the use of these drugs as a treatment option for patients with non-functioning tumours.

show abstract

Malignant carcinoid syndrome: Survival in the octreotide LAR era

Cited by 7 publications

References 0 publications

From somatostatin to octreotide LAR: evolution of a somatostatin analogue

From somatostatin to octreotide LAR: evolution of a somatostatin analogue

Octreotide – A Review of its Use in Treating Neuroendocrine Tumours

Octreotide – A Review of its Use in Treating Neuroendocrine Tumours

Contact Info

Product

Resources

About